Scienture Holdings ( (SCNX) ) just unveiled an announcement.
On March 4, 2025, Scienture Holdings, Inc. entered into an Exclusive Commercial and Supply Agreement with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P., granting Scienture exclusive rights to commercialize REZENOPY® (Naloxone HCl Nasal Spray 10mg) in the United States. This agreement allows Scienture to price, launch, and market the product, which is intended to combat opioid overdoses. The collaboration with Kindeva, which will handle manufacturing, aligns with Scienture’s mission to provide innovative treatment solutions and represents a strategic step in advancing public health initiatives. The agreement includes a joint steering committee to oversee activities and requires Scienture to make milestone and profit-sharing payments to Kindeva.
More about Scienture Holdings
Scienture Holdings, Inc., through its subsidiaries, focuses on providing enhanced value to patients, physicians, and caregivers by developing and distributing novel specialty pharmaceutical products to meet unmet market needs. The company operates in the pharmaceutical industry and offers both branded and generic products across various therapeutic areas.
YTD Price Performance: -73.68%
Average Trading Volume: 901,090
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $14.21M
For detailed information about SCNX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com